Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1/2 Study to Evaluate Safety and Immunogenicity of a Prophylactic Plasmid DNA Booster Vaccine Against SARS-CoV-2 [Covigenix VAX-002] in Generally Healthy Adults 18 Years and Older

NCT06436911 is registered in ClinicalTrials.gov with Entos Pharmaceuticals Inc. as lead sponsor.

NCT NCT06436911
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06436911 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1/2 Study to Evaluate Safety and Immunogenicity of a Prophylactic Plasmid DNA Booster Vaccine Against SARS-CoV-2 [Covigenix VAX-002] in Generally Healthy Adults 18 Years and Older
Lead sponsor
Entos Pharmaceuticals Inc.
Phase
Phase 1/2
Overall status
Completed
Start date
July 22, 2024
Completion date
October 3, 2025
Enrollment
46 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

covid-19